Distinguished in Scleroderma

Flavio R. Sztajnbok

Br, 
Rio De Janeiro, RJ, BR 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Scleroderma
Br, 
Rio De Janeiro, RJ, BR 
OverviewLocationsClinical Research

Overview

Flavio Sztajnbok practices in Rio De Janeiro, Brazil. Mr. Sztajnbok is rated as a Distinguished expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Juvenile Idiopathic Arthritis (JIA), and Systemic Lupus Erythematosus (SLE).

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Scleroderma.

Gender
Male

Locations

Br, Rio De Janeiro, RJ, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3

75 Total Publications

Correction: Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.
Correction: Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.
Journal: Advances in rheumatology (London, England)
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sztajnbok's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile